EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

•Infective endocarditis (IE) has high mortality and morbidity and requires long hospital stays to deliver the antibiotic treatment recommended in clinical practice guidelines.•Dalbavancin (DBV) is a highly effective and safe consolidation therapy for patients with IE due to Gram-positive cocci, with a very low frequency of adverse events.•DBV is an especially cost-effective approach of IE because it facilitates the discharge of patients, reducing their hospital stay.